4164-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-D-2635]

The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals;

Establishing Appropriate Durations of Therapeutic Administration; Extension of Comment

Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA or we) is extending the comment period for a notice that appeared in the <u>Federal Register</u> of September 14, 2016. In that notice, FDA requested comments regarding the establishment of appropriately targeted durations of use of antimicrobial drugs of importance to human medicine (i.e., medically important antimicrobial drugs) when they are administered in the feed or water of food-producing animals for therapeutic purposes. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.

DATES: FDA is extending the comment period on the request for comments published September 14, 2016 (81 FR 63187). Submit either electronic or written comments by March 13, 2017.

ADDRESSES: You may submit comments as follows:

**Electronic Submissions** 

Submit electronic comments in the following way:

- Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to http://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on http://www.regulations.gov.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

## Written/Paper Submissions

Submit written/paper submissions as follows:

- Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets
  Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
  rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Division of Dockets Management, FDA
  will post your comment, as well as any attachments, except for information
  submitted, marked and identified, as confidential, if submitted as detailed in
  "Instructions."

<u>Instructions</u>: All submissions received must include the Docket No. FDA-2016-D-2635 for "Establishing Appropriate Durations of Therapeutic Administration." Received comments will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at http://www.regulations.gov or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on http://www.regulations.gov. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at:

http://www.fda.gov/regulatoryinformation/dockets/default.htm.

4

Docket: For access to the docket to read background documents or the electronic and

written/paper comments received, go to http://www.regulations.gov and insert the docket

number, found in brackets in the heading of this document, into the "Search" box and follow the

prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, rm. 1061,

Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Cindy Burnsteel, Center for Veterinary

Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855,

240-402-0817, cindy.burnsteel@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In the Federal Register of September 14, 2016 (81 FR

63187), FDA solicited comments regarding the establishment of appropriate durations of use of

antimicrobial drugs of importance to human medicine when administered in the feed or water of

food-producing animals for therapeutic purposes with a 90-day comment period.

The Agency has received requests for an extension of the comment period. These

requests conveyed concern that the current 90-day comment period does not allow sufficient

time to develop a meaningful or thoughtful response to the request for comments.

FDA has considered the requests and is extending the comment period for 90 additional

days, until March 13, 2017. The Agency believes that a 90-day extension allows adequate time

for interested persons to submit comments without significantly delaying FDA's consideration of

these important issues.

Dated: November 22, 2016.

Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2016-28660 Filed: 11/28/2016 8:45 am; Publication Date: 11/29/2016]